TSE:FFH

Fairfax Financial (FFH.TO)

2,220.71
+24.98 (1.14%)
as of Jun 5, 2026, 8:00:00 pm Market Open.
281 watching
0
Investor Insights
star iconJun 5, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Fairfax Financial (FFH) has garnered a mixture of perspectives from various experts, predominantly praising its long-term value focus and solid management under Prem Watsa. The company has shown excellent performance in its insurance business, with recent results indicating a strong combined ratio and improved underwriting metrics. However, several analysts caution against entering the stock at present due to the absence of immediate buying catalysts and its high valuation relative to peers. While some experts express ongoing confidence in FFH's long-term prospects, others suggest waiting for a more attractive entry point. Overall, the prevailing sentiment indicates FFH as a stable, defensive choice in the insurance sector, which has been resilient in recent market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Fair Value
review icon
Similar
BRK.A
TOP PICK

It fell recently because the HBC deal is not likely to go well for them. He feels it will go back to $780. Interest rates rising would be good for their insurance companies. They have a hedge against inflation. They tend to make good calls. (Analysts’ target: $749.47).

DON'T BUY

Prem Watsa is often described as the Warren Buffett of Canada. He is opportunistic, not afraid of taking risk. Some of his bets have not worked so well but many have. Insurance companies make money in two ways: core earnings from underwriting, and the investment returns from premiums. Warren Buffett initiated a different approach for investing insurance premiums. Rather than putting it into very safe, but low-yielding, bonds, he invested in stocks. Watsa follows this model and Fairfax has benefitted. The recent rises in interest rates are also very positive for all insurance companies because all of them still buy long-term assets. Fairfax has done nothing for investors for a long while, but he is proposing a top pick in the insurance industry today, and believes that the category has promise.

TOP PICK

He bought it on the break out above $650 back in Q4 2017. He probably won’t hold it much above $780. Yield 1.7%. (Analysts’ price target is $746.97)

BUY

This is a big investment company. He's held this stock for a very long time. It's consolidated the last few years and is beahving well again after some good investments. Buy it now and put it away. It manages a ell-run, diversified portfolio.

TOP PICK

He has been a shareholder of this company for a long time. Underperformed for the last couple of years mainly for some contrarian bets the CEO has made. Just made an investment on Toys r Us that looks interesting for the Real Estate. Good cash position. Good book value. (Analysts’ price target is $746.97)

COMMENT

Run by the brilliant Prem Watsa, but Watsa's made some bad calls about the direction of the markets in recent years. He thinks the street is coming back to this stock. He's owned it for five years. His portfolio is a little strange, like holding Sporting Life. That said, he believes in Prem and will be patient.

HOLD

Management has been very good at calling macro moves. It does not hit his metrics, however. It is a relatively stable stock. A low payout ratio and low yield. You can hold it for stability for the long haul. It is an implied hedge against the market.

PAST TOP PICK

(A Top Pick Dec 1/16. Up 10%.) He still likes this. There is a chance the insurance markets are going to improve with improved pricing after all the catastrophe losses last year. This is a great long-term investor, and if you take a long-term view it’s a company that will be able to compound Book Value at an above average rate. You should think of this as a 5-10 year investment.

COMMENT

Prem Watsa owns a lot of businesses in India, so if you want an indirect way to play India out of a very volatile ETF, this is a way to do it. They also run and Indian ETF. This is an insurance company, so there is a lot of hedging being done. The stock sometimes does better in a poorer market because of the hedges.

PAST TOP PICK

(A Top Pick Oct 31/17. Down 5%.) The stock was moving up, started to round over. This has India. Has insurance interests, which can be affected by the West Coast buyers. He’s at the point where he is trying to decide if this is a real breakdown or should he keep it. Watch this before buying if you are in new investor.

PAST TOP PICK

(A Top Pick Dec 28/16. Up 4.99%.) This has been a little bit all over the board. It would still be a Buy today, but as far as the insurance space goes, there are probably better names. With this one, you get potential for improvement in their insurance underwriting.

COMMENT

Prem Watsa's investing approach is often compared to Warren Buffett's. He believes that over the long-term, the stock price is going to reflect a company's ROE relative to the Price to Book that you are paying for. If you take a very long-term view of this company, it is a fairly safe place to invest. If there was any pullback, this would be a very, very good buy.

PAST TOP PICK

(A Top Pick Oct 31/17, Up 1%) It's been doing very well and thinks that the stock will get into the $750 range. He likes the diversification outside of Canada. It’s an undervalued stocks.

DON'T BUY

Just reported results yesterday and made a huge amount of money, almost $500 million. He likes Prem Watsa. Like everybody else, he is not perfect. Took his hedges off earlier this year. They are very diversified, not just in insurance, but are in India, Ireland, etc. Wouldn't say this was cheap by any metric. He owns the preferreds. Wouldn't be buying now.

TOP PICK

Has been watching this for a very long time. He likes Prem Watsa and the company, but Prem was doing some goofy things with hedging, etc. and it showed in the stock price. He just bought this and thinks there is a lot more room to go. Prem has got back to the basics of investing, and he thinks this is going right back to the top of its trading range of around $750. (Analysts' price target is $699.16.)

Showing 136 to 150 of 455 entries